LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2

S. Popat, K.L. Reckamp, Raffaele Califano, SH Lee, B. Melosky, J. Wang, Yuzhuo Wang, M.R. García Campelo, E. Felip, N. Girard, Ryan D. Gentzler, William N. William, T. Takahashi, Misako Nagasaka, J.M. Bauml, Shalin Shah, B. Diorio, P-L. Chu, B.C. Cho, Antonio Passaro